Johnson and Johnson Hits 52-Week High on Strong Pipeline and Analyst Optimism

# Johnson & Johnson Stock Hits New 52-Week High: Strong Performance & Positive Outlook for JNJ in 2026 **Podcast Episode Description:** Discover why Johnson & Johnson stock (JNJ) is making headlines in February 2026! In this episode, we break down JNJ's impressive climb to a new 52-week high of $247.25, driven by a market cap approaching $593 billion. **What You'll Learn:** - **Latest Stock Performance**: Real-time analysis of JNJ's February 25th, 2026 trading at $246, with 7.2M share volume - **Key Growth Catalysts**: FDA submission for Imaavy (nipocalimab), Tremfya's 3-year UC results, and Darzalex oncology momentum - **Financial Outlook**: Management guidance for $100B+ revenue and $11.53 EPS in 2026 - **Analyst Ratings**: Moderate Buy consensus with price targets ranging from $232-$265 from Goldman Sachs, HSBC, and RBC - **Dividend News**: $1.30 quarterly dividend (2.1% annual yield) payable March 10th - **Long-Term Projections**: LongForecast predicts JNJ could reach $500+ by 2029 Perfect for investors tracking healthcare stocks, pharmaceutical industry trends, and dividend-paying blue chips. Whether you're considering JNJ for your portfolio or monitoring the pharmaceutical sector, this episode delivers actionable insights on one of healthcare's biggest players. **Subscribe for more market analysis and stock updates!** *#JohnsonAndJohnson #JNJStock #StockMarketAnalysis #PharmaceuticalStocks #DividendStocks #HealthcareInvesting #StockNews2026* For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.